Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (September 2021)

35 slides from Aerie Pharmaceuticals's investor presentation, Sep 8, 2021

  1. Slide 1: Company Overview Investor Presentation September 2021

    Company Overview Investor Presentation September 2021 Exhibit 99.1

  2. Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. AR-15512, AR-1105, AR-13503, AR-14034 and AR-6121 are development stage product candidates and are not approved by any regulatory agency. Dex: Dexamethasone Aerie IOP–Reducing Prod

  4. Slide 4: Aerie Overview: 2020 U.S. Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Estimated Aerie TRx Mix Medicare Part D & Medicaid, 62% Commercial & Cash, 24% Graph Source: IQVIA 2020 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker - ~$3B Market, 34M TRx, 55M bottles - 55% of unit volu

  5. Slide 5: Glaucoma Commercialization Focus

    Glaucoma Commercialization Focus Ongoing communication of the MOST Data and coverage via various communication channels Rhopressa® Coverage: 77% Commercial, 92% Med D Rocklatan® Coverage: 75% Commercial, 74% Med D plus 10% Low Income Subsidy Continued execution of the Pulse Strategy, focused on driv

  6. Slide 6: Focused on "Pull-Through" to Gain Share: Med D Coverage Win

    Focused on “Pull-Through” to Gain Share: Example from 05/01/20 Med D Coverage Win IQVIA Payer Details (April 2020-July 2021). For Investor Use Franchise Market Share Apr’201 Jul'21 Part D National TRx Market Share 1.85% 2.39% New Payer Part D TRx Market Share 0.98% 2.24% Market Share Difference ("Ga

  7. Slide 7: Focused on "Pull-Through" to Gain Share: Florida Example

    Focused on “Pull-Through’ to Gain Share: Example from 05/01/20 Med D Coverage Win in Florida Franchise Market Share Apr’201 Jul'21 Part D National TRx Market Share 1.85% 2.39% New Payer Part D TRx Market Share 0.86% 2.75% Market Share Difference ("Gap") -0.99% +0.36% 1 April 2020 was the last month

  8. Slide 8: U.S. Glaucoma Franchise Update

    For Investor Use U.S. Glaucoma Franchise Update Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. Actual Weekly Sales-Out to Pharmacies Data as of 9/3/2021 IQVIA Weekly Data as of 8/27/2021 IQVIA reporting for all reported industry products chan

  9. Slide 9: Aerie Franchise vs Key Brand Competitors

    Aerie Franchise vs Key Brand Competitors Product Jul ‘21 vs. Jul ‘20 TRx Gain / (Loss) Aerie (Rhopressa® & Rocklatan® ) 17% 8,362 Vyzulta® 33% 5,147 Simbrinza® -16% -5,746 Azopt® -62% -22,035 Alphagan® P -8% -5,785 Combigan® -6% -8,421 Lumigan® -5% -8,667 Glaucoma Market 0% 11,080 Aerie franchise co

  10. Slide 10: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b AR-15512 (TRPM8 agonist) Dry Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 SR Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement AR-14034 SR Implant (VEGF-A/B/C/D) wAMD/DM

  11. Slide 11: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health

  12. Slide 12: AR-15512 for Dry Eye: Novel Mechanism of Action

    AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear

  13. Slide 13: AR-15512 (TRPM8 Agonist) for Dry Eye: How It Works

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  14. Slide 14: AR-15512 for Dry Eye: Phase 2a Study

    AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t

  15. Slide 15: Significant efficacy for sign and symptoms with BID dosing

    Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use * = statistical significance ++Data on File AR-15512 is a development stage product candidate and is not approved by any regulatory agency. . Symptoms: SANDE Score P

  16. Slide 16: Dry Eye Clinical Trial Highlights: Schirmer Evaluation

    * = statistical significance ++Data on File AR-15512 is a development stage product candidate and is not approved by any regulatory agency. For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achie

  17. Slide 17: Dry Eye Program: AR-15512

    For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on

  18. Slide 18: AR-15512: COMET-1 Phase 2b Underway

    For Investor Use AR-15512: COMET-1 Phase 2b Underway Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b clinical study commenced October 2020; enrollment completed April 2021 Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% B

  19. Slide 19: 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency

    For Investor Use 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 Frequent intravitreal injections required to maintain vision gains Represents a significant burden for patients and p

  20. Slide 20: Proprietary Drug Delivery Platform for Retinal Disease

    For Investor Use Aerie’s Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible Customizable drug elution, reproducible manufacturing Proprietary bio-erodible formulations, PRINT ® manufacturing Longer treatment duration, reduced injection frequency Enables once or twice p

  21. Slide 21: Proprietary Drug Delivery Technology: A Platform for Future Innovation

    For Investor Use Aerie’s Proprietary Drug Delivery Technology: A Platform for Future Innovation Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg wAMD DME RVO Dry AMD/GA Glaucoma Othe

  22. Slide 22: AR-1105 (Dexamethasone) Implant: Positive Topline Phase 2 Results in RVO

    AR-1105 (Dexamethasone) Implant Positive Topline Phase 2 results in RVO Phase 3 plans underway for the U.S. and Europe for DME Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administration due to smaller needle Potential for fewer ad

  23. Slide 23: AR-1105 Implant: Phase 2 Topline Summary

    AR-1105 (Dexamethasone) Implant: Phase 2 Topline Summary The Phase 2 clinical trial (AR-1105-CS201) was conducted at 19 centers in the United States The objective was to evaluate two clinical formulations of AR-1105, CF-1 and CF-2 (each containing 340 µg dexamethasone), with different release profil

  24. Slide 24: AR-1105 Opportunity

    AR-1105 Opportunity The DME market is growing in the United States and abroad The 6-month sustained efficacy of AR-1105 in the P2 study may render this product, if approved, highly competitive in both the U.S. and European markets AR-1105 may be viewed as a more favorable treatment alternative for a

  25. Slide 25: AR-14034 SR (Axitinib) Implant Opportunity

    AR-14034 SR (Axitinib) Implant Opportunity 1. Market Scope Estimates 2020; http://market-scope.com/ Aflibercept Ranibizumab Bevacizumab Brolucizumab Axitinib For Investor Use 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 20251 Current anti-VEGF pipeline dominated by longer duration products

  26. Slide 26: Axitinib Is Preferred Small Molecule for VEGF Inhibition

    Axitinib Is Preferred Small Molecule for VEGF Inhibition Pan-VEGF receptor inhibitor (inhibits all isoforms of VEGF-R) Approved for systemic use in 2012 for the treatment of renal cell carcinoma Higher potency and less off-target activity than other small molecule inhibitors Most selective For Inves

  27. Slide 27: Axitinib Implant: Results Support Up to 12 Months Duration

    Axitinib Implant: Results Support Up to 12 Months Duration in Clinic Proprietary polymer blend produces optimal drug elution profile Maintains high elution rate over time Drug release rate in rabbits predicts up to 12-months duration (once a year injection) in clinic Aerie rabbit data accurately pre

  28. Slide 28: Ophthalmic Steroid Market Opportunity

    Ophthalmic Steroid Market Opportunity There are approximately 11 million steroid TRx units in the US market1 Potency and corneal penetration are key attributes of any topical steroid Strong steroids represent 80% of the marketplace lead by prednisolone Loteprednol is the leading soft steroid All ste

  29. Slide 29: Concept and Chemistry: ROCK'Sters ROCK Inhibitor-Linked Steroid

    For Investor Use Concept and Chemistry: ROCK’Sters ROCK inhibitor-Linked Steroid ROCK’Sters are a proprietary class of potent ocular corticosteroids linked to ROCK inhibitors (ROCKi) Rationale for design: to leverage the anti-fibrotic and IOP-lowering activities of ROCK inhibitors to generate potent

  30. Slide 30: In Vivo Efficacy: Mouse Endotoxin-Induced Uveitis Model

    For Investor Use In Vivo Efficacy: Mouse Endotoxin-Induced Uveitis Model (24 hrs.) AR-6121 compared to 0.05% Durezol® AR-6121 is at least as effective as Durezol® in the mouse EIU model EIU has been used to model human anterior uveitis: to investigate the dynamics of resolving inflammation (e.g., le

  31. Slide 31: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 First Phase 3 trial in Japan fully enrolled; Topline results expected in Q4 2021 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2021. *TRx calculated from I

  32. Slide 32: Japan Phase 3 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  33. Slide 33: Japan Phase 2 Study Topline Results: IOP vs Placebo

    P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use

  34. Slide 34: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019 and for Roclanda® (Rocklatan®) in January 2021 Mercury 3: Reported successful 90-day topline data in September 2020; Rocklatan® (known as Roclanda® in Europe) achieved non-

  35. Slide 35: Summary: Key Priorities

    For Investor Use Summary Key Priorities Driving continued Rhopressa® and Rocklatan® volume growth in the U.S. Globalization Strategy Japan: Santen collaboration commencing and first Phase 3 trial underway Europe: Significant interest from potential collaborators Ireland Manufacturing Facility approv

Aerie Pharmaceuticals — Investor Presentation (September 2021) on 6ix